Cited by 770Immune cells in cancerCancer Immunotherapy and BiomarkersChemokine receptors and signaling

The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.

Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy

Open access

Highfill, Steven L., Cui, Yongzhi, Giles, Amber J., Smith, Jillian P., Zhang, Hua, Morse, Elizabeth, Kaplan, Rosandra N., Mackall, Crystal L.·2014·Science Translational Medicine

DOI 10.1126/scitranslmed.3007974PMC PMC6980372

Open this paper in CoChat — free account

Abstract

Preventing trafficking of myeloid-derived suppressor cells to the tumor site enhances the efficiency of checkpoint blockade.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.3007974

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · cited 1×
“Signaling of PD1 on T cells via PD-L1 (B7-H1) or PD-L2 (B7-DC) inhibits T cell receptor–mediated activation by recruitment of the SHP2 phosphatase (2).”
Background
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 1×
“Combination regimens appear to be even more potent with response rates of 53% in metastatic melanoma (22).”
Background
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 2×
“These results are consistent with previous reports demonstrating that GrMDSCs at the tumor site are highly dependent on migration from the BM or spleen and undergo minimal proliferation within the tumor bed (13).”
BackgroundResult
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,261
Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,259 · cited 1×
“Since its discovery in 1992 (5), it has become increasingly apparent that cancers often use PD1 signaling to mediate immune escape.”
Background
The B7 family revisited
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
The Interleukin-8 Pathway in Cancer
Waugh, D. J. J., & Wilson, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4843 · Cited by 2,103 · cited 1×
“The elevations in CXCL8 were higher than that for CXCL1, consistent with a substantial literature implicating CXCL8 in various aspects of tumor growth (37).”
Result
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868 · cited 1×
“Splenocytes were restimulated with the following synthetic HY-specific peptides: (i) Uty: the immunodominant Db–restricted HY-derived peptide corresponding to amino acids 245 to 253 (WMHHNMDLI) of the Uty gene product; (ii) Dby: the immunodominant I-Ab–restricted (NAGFNSNRANSSRSS) HYderived peptide; and as specific co…”
Method
Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J., Nagaraj, S., Collazo, M. M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645 · cited 1×
“All-trans retinoic acid (ATRA) appears capable of differentiating immature, suppressive MoMDSCs into mature, nonsuppressive dendritic cells, macrophages, and granulocytes, but this may also target cells other than MDSCs (such as T cells) and may potentially cause MDSC-independent effects (17, 46).”
Background
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer
Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378
Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity.
Movahedi, K., Guilliams, M., van den Bossche, J., den Bergh, R. V., Gysemans, C., Beschin, A., Baetselier, P. D., & Ginderachter, J. V. V. (2008) · Blood · doi:10.1182/blood-2007-07-099226 · Cited by 1,352
Tissue expression of PD-L1 mediates peripheral T cell tolerance
Keir, M. E., Liang, S. C., Guleria, I., Latchman, Y. E., Qipo, A., Albacker, L. A., Koulmanda, M., Freeman, G. J., Sayegh, M. H., & Sharpe, A. H. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051776 · Cited by 1,244
C hemokines in I nnate and A daptive H ost D efense : Basic Chemokinese Grammar for Immune Cells
Rot, A., & von Andrian, U. H. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104543 · Cited by 1,209 · cited 1×
“In humans, CXCL8 and CXCL6 signal through both CXCR1 and CXCR2, whereas the other CXC chemokine ligands (CXCL1, CXCL2, CXCL3, CXCL5, and CXCL7) signal only via CXCR2 (30).”
Background
Abrogation of TGFβ Signaling in Mammary Carcinomas Recruits Gr-1+CD11b+ Myeloid Cells that Promote Metastasis
Yang, L., Huang, J., Ren, X., Gorska, A. E., Chytil, A., Aakre, M., Carbone, D. P., Matrisian, L. M., Richmond, A., Lin, P. C., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2007.12.004 · Cited by 918 · cited 1×
“(33) showed that Gr1CD11b MDSCs are recruited into murine mammary carcinomas via a CXCR2-dependent mechanism and, once there, act to promote tumor invasion and metastasis.”
Background
Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis
Sparmann, A., & Bar‐Sagi, D. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.028 · Cited by 880 · cited 1×
“CXCL8 is induced by several oncogenes including RET, Ras (38, 39), and EGFR (40) and has been implicated in tumor survival, angiogenesis, and epithelial-mesenchymal transition (41).”
Background
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G., Lobo, J. R., Sengupta, S., Chen, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406351101 · Cited by 776 · cited 1×
“Tumor expression of PD-L1 inhibits tumor-reactive T cells in animal models (6–8), and some clinical studies show correlations between tumor expression of PD-L1 and PD-L2 and adverse outcomes (9, 10).”
Background
Myeloid suppressor cells in cancer: Recruitment, phenotype, properties, and mechanisms of immune suppression
Serafini, P., Borrello, I., & Bronte, V. (2005) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.07.005 · Cited by 775
Arginase I–Producing Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma Are a Subpopulation of Activated Granulocytes
Rodrı́guez, P. C., Ernstoff, M. S., Hernandez, C., Atkins, M. B., Zabaleta, J., Sierra, R. A., & Ochoa, A. C. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1921 · Cited by 774
Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells
Molon, B., Ugel, S., Pozzo, F. D., Soldani, C., Zilio, S., Avella, D., Palma, A. D., Mauri, P., Monegal, A., Rescigno, M., et al. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.20101956 · Cited by 685 · cited 1×
“(29), which showed that CCL2 undergoes posttranslational modification (nitration) within the tumor bed, which makes it less effective in attracting CCR2 cells.”
Background
Hierarchy of immunosuppressive strength among myeloid‐derived suppressor cell subsets is determined by GM‐CSF
Dolcetti, L., Peranzoni, E., Ugel, S., Marigo, I., Fernández, A., Mesa, C., Geilich, M., Winkels, G., Traggiai, E., Casati, A., et al. (2009) · European Journal of Immunology · doi:10.1002/eji.200939903 · Cited by 568
Regulation of T Cell Receptor CD3ζ Chain Expression byl-Arginine
Rodrı́guez, P. C., Zea, A. H., Culotta, K. S., Zabaleta, J., Ochoa, J. B., & Ochoa, A. C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110675200 · Cited by 537
Arginase, Prostaglandins, and Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma
Ochoa, A. C., Zea, A. H., Hernandez, C., & Rodrı́guez, P. C. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2197 · Cited by 489 · cited 1×
“Scie therefore that although MDSCs can mediate systemic immunosuppression (36), local immunosuppression appears to be the major limiting factor in the response to anti-PD1 therapy in this model system.”
Background
CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis
Katoh, H., Wang, D., Daikoku, T., Sun, H., Dey, S. K., & DuBois, R. N. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.10.009 · Cited by 477 · cited 1×
“(34) recently showed that deletion of CXCR2 in a mouse model of colitisassociated tumorigenesis reduced the number of GrMDSCs within the tumor, which had a marked effect on T cell function.”
Background
Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway
Elias, K. M., Laurence, A. D. J., Davidson, T. S., Stephens, G. L., Kanno, Y., Shevach, E. M., & O’Shea, J. J. (2007) · Blood · doi:10.1182/blood-2007-06-096438 · Cited by 449
Induction of interleukin-8 preserves the angiogenic response in HIF-1α–deficient colon cancer cells
Mizukami, Y., Jo, W., Duerr, E., Gala, M. K., Li, J., Zhang, X., Zimmer, M. A., Iliopoulos, O., Zukerberg, L. R., Kohgo, Y., et al. (2005) · Nature Medicine · doi:10.1038/nm1294 · Cited by 407 · cited 1×
“CXCL8 is induced by several oncogenes including RET, Ras (38, 39), and EGFR (40) and has been implicated in tumor survival, angiogenesis, and epithelial-mesenchymal transition (41).”
Background
IL-8 Signaling Plays a Critical Role in the Epithelial–Mesenchymal Transition of Human Carcinoma Cells
Fernando, R. I., Castillo, M. D., Litzinger, M. T., Hamilton, D. H., & Palena, C. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0156 · Cited by 405 · cited 1×
“CXCL8 is induced by several oncogenes including RET, Ras (38, 39), and EGFR (40) and has been implicated in tumor survival, angiogenesis, and epithelial-mesenchymal transition (41).”
Background
618: Costimulatory B7-H1 In Renal Cell Carcinoma Patients: Indicator of Tumor Aggressiveness and Potential Therapeutic Target
Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G., Lobo, J. R., Sengupta, S., Chen, L., et al. (2005) · The Journal of Urology · doi:10.1016/s0022-5347(18)34858-4 · Cited by 386
Monocytic CCR2+ Myeloid-Derived Suppressor Cells Promote Immune Escape by Limiting Activated CD8 T-cell Infiltration into the Tumor Microenvironment
Lesokhin, A. M., Hohl, T. M., Kitano, S., Cortez, C. A., Hirschhorn-Cymerman, D., Avogadri, F., Rizzuto, G. A., Lazarus, J. J., Pamer, E. G., Houghton, A. N., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1792 · Cited by 380
Increased Serum Interleukin-8 in Patients with Early and Metastatic Breast Cancer Correlates with Early Dissemination and Survival
Benoy, I. H., Salgado, R., van Dam, P. A., Geboers, K., Marck, E. V., Scharpé, S., Vermeulen, P. B., & Dirix, L. Y. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0812 · Cited by 354 · cited 2×
“It is of interest to note that the CXCL8 levels measured in patients with metastatic pediatric cancers were about one log higher than those measured in the serum of women with metastatic breast cancer (42).”
BackgroundResult
Myeloid Suppressor Cell Depletion Augments Antitumor Activity in Lung Cancer
Srivastava, M. K., Zhu, L. X., Harris‐White, M. E., Kar, U. K., Huang, M., Johnson, M. F., Lee, J. M., Elashoff, D. A., Strieter, R. M., Dubinett, S. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040677 · Cited by 215 · cited 1×
“The monoclonal anti-Gr1 antibody (clone RB6-8C5) effectively depletes MDSCs in tumor-bearing mice and enhances antitumor reactivity (44, 45), but human cells do not express a marker homologous to mouse Gr1, and widespread depletion of myeloid subsets would be expected to induce profound immunosuppression.”
Background
Murine CXCR1 Is a Functional Receptor for GCP-2/CXCL6 and Interleukin-8/CXCL8
Fan, X., Patera, A. C., Pong-Kennedy, A., Deno, G., Gonsiorek, W., Manfra, D. J., Vassileva, G., Zeng, M., Jackson, C., Sullivan, L., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m607705200 · Cited by 204
Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma
Kapanadze, T. G., Gamrekelashvili, J., Ma, C., Chan, C., Zhao, F., Hewitt, S. M., Zender, L., Kapoor, V., Felsher, D. W., Manns, M. P., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.06.010 · Cited by 186
Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection.
Seung, L. P., Rowley, D. A., Dubey, P., & Schreiber, H. W. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.14.6254 · Cited by 176 · cited 1×
“The monoclonal anti-Gr1 antibody (clone RB6-8C5) effectively depletes MDSCs in tumor-bearing mice and enhances antitumor reactivity (44, 45), but human cells do not express a marker homologous to mouse Gr1, and widespread depletion of myeloid subsets would be expected to induce profound immunosuppression.”
Background
Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer
Zhang, H., Maric, I., DiPrima, M., Khan, J. I., Orentas, R. J., Kaplan, R. N., & Mackall, C. L. (2013) · Blood · doi:10.1182/blood-2012-08-449413 · Cited by 164
Self-citation
Mononuclear myeloid-derived "suppressor" cells express RAE-1 and activate natural killer cells.
Nausch, N., Galani, I., Schlecker, E., & Cerwenka, A. (2008) · Blood · doi:10.1182/blood-2008-03-143776 · Cited by 163
CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma.
Weigel, B. J., Rodeberg, D. A., Krieg, A. Μ., & Blazar, B. R. (2003) · PubMed · Cited by 133
Granulocytic myeloid-derived suppressor cells are cryosensitive and their frequency does not correlate with serum concentrations of colony-stimulating factors in head and neck cancer
Trellakis, S., Bruderek, K., Hütte, J., Elian, M., Hoffmann, T. K., Lang, S., & Brandau, S. (2012) · Innate Immunity · doi:10.1177/1753425912463618 · Cited by 96
Enhanced suppressive capacity of tumor‐infiltrating myeloid‐derived suppressor cells compared with their peripheral counterparts
Maenhout, S. K., Lint, S. V., Emeagi, P. U., Thielemans, K., & Aerts, J. L. (2013) · International Journal of Cancer · doi:10.1002/ijc.28449 · Cited by 75 · cited 1×
“Indeed, although numerous reports describe the MoMDSCs as the more suppressive subtype (25–27), several previous models involving murine melanoma, lung carcinoma, and lymphoma models observed that GrMDSCs are more suppressive (28).”
Background
Safeguarding Patients in Clinical Trials with High Mortality Rates
Freeman, B. D., Danner, R. L., BANKS, S. M., & Natanson, C. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.2.2011028 · Cited by 68
Murine rhabdomyosarcoma is immunogenic and responsive to T‐cell‐based immunotherapy
Meadors, J. L., Cui, Y., Chen, Q., Song, Y., Khan, J. I., Merlino, G. T., Tsokos, M., Orentas, R. J., & Mackall, C. L. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.23048 · Cited by 37
Self-citation
CXCR2-The Receptor to Hit?
Reutershan, J. (2006) · Drug News & Perspectives · doi:10.1358/dnp.2006.19.10.1068009 · Cited by 35 · cited 1×
“In humans, CXCL1 and CXCL8 are the major ligands for CXCR2 (19).”
Background
The EGF Receptor and HER2 Participate in TNF-α-Dependent MAPK Activation and IL-8 Secretion in Intestinal Epithelial Cells
Jijon, H. B., Buret, A. G., Hirota, C. L., Hollenberg, M. D., & Beck, P. L. (2012) · Mediators of Inflammation · doi:10.1155/2012/207398 · Cited by 32 · cited 1×
“CXCL8 is induced by several oncogenes including RET, Ras (38, 39), and EGFR (40) and has been implicated in tumor survival, angiogenesis, and epithelial-mesenchymal transition (41).”
Background
Unresponsiveness of Intrahepatic Lymphocytes to Bacterial Superantigen: Rapid Development of Suppressive Mac-1high Cells in the Mouse Liver
Terabe, M., Shimizu, M., Mabuchi, A., Matui, S., Morikawa, H., Kaneda, K., Kakiuchi, T., & Yokomuro, K. (2000) · Hepatology · doi:10.1053/jhep.2000.9875 · Cited by 15

Sorted by citations

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
“For example, tumors secrete ligands CCL5, CCL7, and CXCL8, bind to their receptors CCR1 or CXCR2 expressed on subtypes of MDSCs (Highfill et al., 2014), and attract MDSCs in the tumor microenvironment.”
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 3,058
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
Veglia, F., Sanseviero, E., & Gabrilovich, D. I. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00490-y · Cited by 1,940
Neutrophils in cancer: Neutral no more
Coffelt, S. B., Wellenstein, M. D., & de Visser, K. E. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.52 · Cited by 1,830
Myeloid-Derived Suppressor Cells
Gabrilovich, D. I. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0297 · Cited by 1,935
“The level of MDSCs is associated with patient responses to CTLA-4/ipilimumab (58, 59) and PD-1 (60, 61) inhibition.”
Background

See all 770

Authors: Highfill, S. L., Cui, Y., Giles, A. J., Smith, J. P., Zhang, H., Morse, E., Kaplan, R. N., & Mackall, C. L.
Affiliations: National Institutes of Health (US)
Corresponding author: Mackall, Crystal L.
ORCID: Highfill, Steven L.
Cui, Yongzhi
Giles, Amber J.
Zhang, Hua
Kaplan, Rosandra N.
Mackall, Crystal L.
Venue: Science Translational Medicine
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2014-05-21
Volume: 6
Issue: 237
Pages: 237ra67-237ra67
ISSN: 1946-6234 (ISSN-L)
1946-6242
DOI: 10.1126/scitranslmed.3007974
PMC: PMC6980372
OpenAlex: W2171524684
Cited by: 767
References: 50
Citations by year: 2026: 55 · 2025: 62 · 2024: 57 · 2023: 83 · 2022: 73 · 2021: 100 · 2020: 91 · 2019: 60 · 2018: 52 · 2017: 52 · 2016: 38 · 2015: 31 · 2014: 12
FWCI: 20.24
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Science Translational Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health
National Cancer Institute (Z01BC011072, Z01BC010566, Z01SC010289)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
Keywords: CXCR2, myeloid-derived suppressor cells, tumor immune evasion, anti-PD-1 therapy, rhabdomyosarcoma, pediatric sarcoma, interleukin-8, PD-L1, tumor immunosuppression
MeSH terms: Adolescent, Adult, Animals, Antibodies, Monoclonal, Antigens, Ly, Antineoplastic Combined Chemotherapy Protocols, Chemotaxis, Child, Child, Preschool, Female, Humans, Male, Mice, Inbred C57BL, Prognosis, Rhabdomyosarcoma, Time Factors, Neoplastic Stem Cells, Case-Control Studies, Cytokines, Interleukin-8, Mice, Knockout, Tumor Escape, Receptors, Interleukin-8B, CD11b Antigen, Cell Line, Tumor, Tumor Burden, Mice, Chemokine CXCL1, Young Adult, Tumor Microenvironment, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks